JP2010514835A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514835A5 JP2010514835A5 JP2009544484A JP2009544484A JP2010514835A5 JP 2010514835 A5 JP2010514835 A5 JP 2010514835A5 JP 2009544484 A JP2009544484 A JP 2009544484A JP 2009544484 A JP2009544484 A JP 2009544484A JP 2010514835 A5 JP2010514835 A5 JP 2010514835A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- compound according
- linking residue
- group
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 238000006467 substitution reaction Methods 0.000 claims 9
- AHUAWUAHWZIPJC-UHFFFAOYSA-M sodium;2-(3-hexoxy-2-hydroxypropoxy)benzoate Chemical compound [Na+].CCCCCCOCC(O)COC1=CC=CC=C1C([O-])=O AHUAWUAHWZIPJC-UHFFFAOYSA-M 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- 108010032595 Antibody Binding Sites Proteins 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 claims 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 150000004283 biguanides Chemical class 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229950004994 meglitinide Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000269 nucleophilic effect Effects 0.000 claims 1
- 150000001467 thiazolidinediones Chemical class 0.000 claims 1
- 0 CC(C)(C(*)=O)NC([C@@](*)Cc1cnc[n]1)=O Chemical compound CC(C)(C(*)=O)NC([C@@](*)Cc1cnc[n]1)=O 0.000 description 2
- KIDRGEYNFGIWLV-BYPYZUCNSA-N C[N-](C)([C@H](C(N)=O)O)P Chemical compound C[N-](C)([C@H](C(N)=O)O)P KIDRGEYNFGIWLV-BYPYZUCNSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87904807P | 2007-01-05 | 2007-01-05 | |
| US60/879,048 | 2007-01-05 | ||
| US93983107P | 2007-05-23 | 2007-05-23 | |
| US60/939,831 | 2007-05-23 | ||
| US94531907P | 2007-06-20 | 2007-06-20 | |
| US60/945,319 | 2007-06-20 | ||
| PCT/IE2008/000001 WO2008081418A1 (en) | 2007-01-05 | 2008-01-07 | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012089113A Division JP2012184232A (ja) | 2007-01-05 | 2012-04-10 | グルカゴン様タンパク質１受容体（ｇｌｐ−１ｒ）アゴニスト化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010514835A JP2010514835A (ja) | 2010-05-06 |
| JP2010514835A5 true JP2010514835A5 (enExample) | 2011-01-06 |
| JP5009376B2 JP5009376B2 (ja) | 2012-08-22 |
Family
ID=39313161
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009544484A Expired - Fee Related JP5009376B2 (ja) | 2007-01-05 | 2008-01-07 | グルカゴン様タンパク質１受容体（ｇｌｐ−１ｒ）アゴニスト化合物 |
| JP2012089113A Pending JP2012184232A (ja) | 2007-01-05 | 2012-04-10 | グルカゴン様タンパク質１受容体（ｇｌｐ−１ｒ）アゴニスト化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012089113A Pending JP2012184232A (ja) | 2007-01-05 | 2012-04-10 | グルカゴン様タンパク質１受容体（ｇｌｐ−１ｒ）アゴニスト化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090098130A1 (enExample) |
| EP (1) | EP2118131A1 (enExample) |
| JP (2) | JP5009376B2 (enExample) |
| KR (2) | KR101224335B1 (enExample) |
| AU (1) | AU2008203641B2 (enExample) |
| BR (1) | BRPI0806308A2 (enExample) |
| CA (1) | CA2674112A1 (enExample) |
| MX (1) | MX2009007290A (enExample) |
| NZ (1) | NZ577686A (enExample) |
| WO (1) | WO2008081418A1 (enExample) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090098130A1 (en) * | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| WO2009099763A1 (en) | 2008-01-30 | 2009-08-13 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
| US8293714B2 (en) * | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
| US20120148586A1 (en) | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| CA2784757A1 (en) * | 2009-12-16 | 2011-07-07 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| US8765920B2 (en) | 2009-12-23 | 2014-07-01 | The Scripps Research Institute | Tyrosine bioconjugation through aqueous Ene-like reactions |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| CA2803164C (en) | 2010-06-24 | 2018-08-21 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| JP5913307B2 (ja) | 2010-07-12 | 2016-04-27 | コヴェックス・テクノロジーズ・アイルランド・リミテッド | 多機能性抗体複合体 |
| US9688735B2 (en) | 2010-08-20 | 2017-06-27 | Wyeth Llc | Designer osteogenic proteins |
| WO2012023113A2 (en) | 2010-08-20 | 2012-02-23 | Wyeth Llc | Designer osteogenic proteins |
| WO2012059873A2 (en) * | 2010-11-05 | 2012-05-10 | Covx Technologies Ireland, Ltd. | Anti-diabetic compounds |
| UA126465C2 (uk) | 2011-06-10 | 2022-10-12 | Ханмі Сайенс Ко., Лтд. | Пептид, що має активність оксинтомодуліну, та фармацевтична композиція для лікування ожиріння, яка його містить |
| PL2721062T3 (pl) | 2011-06-17 | 2019-05-31 | Hanmi Science Co Ltd | Koniugat zawierający oksyntomodulinę oraz fragment immunoglobuliny i jego zastosowanie |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2793950A2 (en) | 2011-12-20 | 2014-10-29 | Pfizer Inc | Improved processes for preparing peptide conjugates and linkers |
| CN104114183A (zh) | 2011-12-20 | 2014-10-22 | 印第安纳大学研究及科技有限公司 | 用于治疗糖尿病的基于ctp的胰岛素类似物 |
| AU2012356219B2 (en) | 2011-12-22 | 2016-03-31 | Covx Technologies Ireland Limited | Anti-diabetic compounds |
| JP6413127B2 (ja) | 2012-01-09 | 2018-10-31 | コヴェックス・テクノロジーズ・アイルランド・リミテッド | 変異抗体およびそのコンジュゲーション |
| SG11201407860PA (en) * | 2012-06-14 | 2014-12-30 | Sanofi Sa | Exendin-4 peptide analogues |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| CN108383902A (zh) * | 2012-09-26 | 2018-08-10 | 印第安纳大学研究及科技有限公司 | 胰岛素类似物二聚体 |
| UA116217C2 (uk) * | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| WO2014064215A1 (en) | 2012-10-24 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| PT2916819T (pt) | 2012-11-06 | 2019-10-28 | Hanmi Pharm Ind Co Ltd | Formulação líquida de conjugado proteico que compreende a oxintomodulina e um fragmento de imunoglobulina. |
| JP2016506401A (ja) * | 2012-12-21 | 2016-03-03 | サノフイ | 二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体 |
| JP6538645B2 (ja) | 2013-03-14 | 2019-07-03 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | インスリン‐インクレチン複合物 |
| CN104371019B (zh) | 2013-08-13 | 2019-09-10 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
| EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| WO2015086731A1 (en) * | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| AR098614A1 (es) * | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Compuesto para el tratamiento de hipoglicemia severa |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| CN107001441A (zh) | 2014-09-24 | 2017-08-01 | 印第安纳大学研究及科技有限公司 | 脂质化的基于酰胺的胰岛素前药 |
| US10232020B2 (en) | 2014-09-24 | 2019-03-19 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
| KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| CR20170293A (es) | 2014-12-30 | 2017-11-03 | Hanmi Pharm Ind Co Ltd | Derivados de glucagón con estabilidad mejorada |
| ES2833099T3 (es) | 2015-02-11 | 2021-06-14 | Gmax Biopharm Llc | Preparación de disolución estabilizada de una proteína de fusión de un anticuerpo de GLP-1R farmacéutica |
| WO2016151018A1 (en) | 2015-03-24 | 2016-09-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment of diabetes |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| WO2016198604A1 (en) * | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as dual glp-1 /glucagon receptor agonists |
| TN2017000555A1 (en) * | 2015-06-30 | 2019-04-12 | Hanmi Pharm Ind Co Ltd | Glucagon derivative and a composition comprising a long acting conjugate of the same |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| CR20180378A (es) | 2015-12-23 | 2018-12-06 | Amgen Inc | Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1 |
| JP6712323B2 (ja) | 2015-12-31 | 2020-06-17 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体 |
| SG11201811697SA (en) | 2016-06-29 | 2019-01-30 | Hanmi Pharmaceutical Co Ltd | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof |
| KR102781241B1 (ko) * | 2017-01-17 | 2025-03-14 | 암젠 인크 | 위 저해 펩타이드 수용체(gipr)에 대한 길항제에 접합된 glp-1 수용체 작용제를 사용하여 대사 장애를 치료 또는 개선하는 방법 |
| MX2019013919A (es) | 2017-06-20 | 2020-01-21 | Amgen Inc | Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1. |
| JP7250706B2 (ja) | 2017-06-21 | 2023-04-03 | アムジエン・インコーポレーテツド | 胃抑制ペプチド受容体（ｇｉｐｒ）に対するアンタゴニスト結合タンパク質／ｇｌｐ－１受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法 |
| JP7495420B2 (ja) | 2019-02-20 | 2024-06-04 | ノヴォ ノルディスク アー／エス | アミノアシル－ｔＲＮＡ合成酵素およびこの使用 |
| GB201908424D0 (en) * | 2019-06-12 | 2019-07-24 | Imp College Innovations Ltd | Novel compounds |
| CN111410686B (zh) * | 2020-03-18 | 2021-02-26 | 南京枫璟生物医药科技有限公司 | Glp-1r激活剂的分子改构及其二聚体在治疗代谢病中的应用 |
| EP4259646A1 (en) | 2020-12-11 | 2023-10-18 | IP2IPO Innovations Limited | Novel compounds |
| CA3210657A1 (en) * | 2021-02-16 | 2022-08-25 | Indiana University Research And Technology Corporation | Glucagon-like peptide-1 receptor antagonists |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3719667A (en) * | 1970-08-24 | 1973-03-06 | Lilly Co Eli | Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters |
| US3840556A (en) * | 1971-05-28 | 1974-10-08 | Lilly Co Eli | Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby |
| US5567610A (en) * | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5216132A (en) * | 1990-01-12 | 1993-06-01 | Protein Design Labs, Inc. | Soluble t-cell antigen receptor chimeric antigens |
| DE69126871T2 (de) * | 1990-04-06 | 1998-03-12 | Jolla Cancer Res Found | Verfahren und verbindung zur behandlung von thrombose |
| US5229275A (en) * | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US6080840A (en) * | 1992-01-17 | 2000-06-27 | Slanetz; Alfred E. | Soluble T cell receptors |
| US5573905A (en) * | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5424286A (en) * | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US5733757A (en) * | 1995-12-15 | 1998-03-31 | The Scripps Research Institute | Aldolase catalytic antibody |
| US5869046A (en) * | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) * | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| GB9722131D0 (en) * | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US6326176B1 (en) * | 1997-12-18 | 2001-12-04 | The Scripps Research Institute | Aldol condensations by catalytic antibodies |
| US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| CA2372794A1 (en) * | 1999-05-14 | 2000-11-23 | Mcgill University | Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction |
| SI1180121T1 (en) * | 1999-05-17 | 2004-04-30 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
| US6294374B1 (en) * | 1999-10-08 | 2001-09-25 | The Scripps Research Institute | Use of catalytic antibodies for synthesizing epothilone |
| ES2311560T3 (es) * | 2000-12-07 | 2009-02-16 | Eli Lilly And Company | Proteinas de fusion glp-1. |
| US20030045477A1 (en) * | 2001-07-26 | 2003-03-06 | Fortuna Haviv | Peptides having antiangiogenic activity |
| JP4629047B2 (ja) * | 2003-06-12 | 2011-02-09 | イーライ リリー アンド カンパニー | Ｇｌｐ−１アナログ複合タンパク質 |
| PT1641483E (pt) * | 2003-06-12 | 2008-04-29 | Lilly Co Eli | Proteínas de fusão |
| AU2003254882A1 (en) * | 2003-08-07 | 2005-02-25 | Fujitsu Media Devices Limited | Micro switching element and method of manufacturing the element |
| CA2550050A1 (en) * | 2003-12-18 | 2005-06-30 | Novo Nordisk A/S | Novel glp-1 analogues linked to albumin-like agents |
| US7442778B2 (en) * | 2004-09-24 | 2008-10-28 | Amgen Inc. | Modified Fc molecules |
| EP1853294A4 (en) * | 2005-03-03 | 2010-01-27 | Covx Technologies Ireland Ltd | ANTIANGIOGENIC COMPOUNDS |
| GB2427360A (en) * | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| JP4897050B2 (ja) * | 2006-11-10 | 2012-03-14 | コヴェックス・テクノロジーズ・アイルランド・リミテッド | 抗血管形成化合物 |
| US20090098130A1 (en) * | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| JP2010538069A (ja) * | 2007-09-07 | 2010-12-09 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | エキセンディン−４およびエキセンディン−３の類似体 |
-
2008
- 2008-01-04 US US11/969,850 patent/US20090098130A1/en not_active Abandoned
- 2008-01-07 CA CA002674112A patent/CA2674112A1/en not_active Abandoned
- 2008-01-07 AU AU2008203641A patent/AU2008203641B2/en not_active Ceased
- 2008-01-07 JP JP2009544484A patent/JP5009376B2/ja not_active Expired - Fee Related
- 2008-01-07 BR BRPI0806308-7A patent/BRPI0806308A2/pt not_active IP Right Cessation
- 2008-01-07 WO PCT/IE2008/000001 patent/WO2008081418A1/en not_active Ceased
- 2008-01-07 KR KR1020097013938A patent/KR101224335B1/ko not_active Expired - Fee Related
- 2008-01-07 NZ NZ577686A patent/NZ577686A/en not_active IP Right Cessation
- 2008-01-07 KR KR1020127014446A patent/KR20120083510A/ko not_active Ceased
- 2008-01-07 MX MX2009007290A patent/MX2009007290A/es active IP Right Grant
- 2008-01-07 EP EP08702600A patent/EP2118131A1/en not_active Withdrawn
-
2012
- 2012-04-10 JP JP2012089113A patent/JP2012184232A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2432361C2 (ru) | Соединения агонисты рецептора глюкагоноподобного белка-1 (glp-1r) | |
| JP2011500725A5 (enExample) | ||
| RU2476441C2 (ru) | Cd19-связывающие средства и их применение | |
| JP2010509315A5 (enExample) | ||
| JP2021531826A5 (enExample) | ||
| JP2024500242A5 (enExample) | ||
| US20180016352A1 (en) | Targeting constructs for delivery of payloads | |
| JP2009225799A5 (enExample) | ||
| WO2013093720A3 (en) | Anti-diabetic compounds | |
| JP2024501894A5 (enExample) | ||
| JP2022512778A5 (enExample) | ||
| RS59072B1 (sr) | Anti-fcrn antitela | |
| JP2012522512A5 (enExample) | ||
| WO2008101231A3 (en) | Methods and compositions for treating and diagnosing kidney disease | |
| WO2007134037A3 (en) | Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments | |
| JP2026026483A (ja) | 標的化デンドリマー複合体 | |
| JP2011528710A5 (enExample) | ||
| JP2014522850A5 (enExample) | ||
| JP2022541517A5 (enExample) | ||
| CN111712520A (zh) | 磷脂酰肌醇聚糖3抗体及其偶联物 | |
| SI2530091T1 (en) | Anti-dll3 antibody | |
| JP2021527640A5 (enExample) | ||
| RU2012106200A (ru) | Агонисты рецептора глюкагоноподобного пептида-1 (glp-1r) для лечения аутоиммунных расстройств | |
| JP2018510864A5 (enExample) | ||
| RS56298B1 (sr) | Antitelo koje vezuje il-17a i il-17f |